SCHEMBL13931027

SCHEMBL13931027

CCOC(=O)Cc1cn(Cc2ccc(Oc3ccccc3)cc2)c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ICMT O60725 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.50
PLA2G2A P14555 2/20 0.49
F2RL3 Q96RI0 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
CHRM1 P11229 1/20 0.48
CHRNB2 P17787 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
HTR6 P50406 1/20 0.47
HDAC10 Q969S8 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8180741 0.94 KMT2A (0.52) ICMTL3MBTL1POLBPLA2G2AF2RL3
SCHEMBL8182875 0.91 LMNA (0.50) ICMTL3MBTL1POLBPLA2G2AF2RL3
SCHEMBL13931024 0.90 LMNA (0.54) ICMTL3MBTL1PLA2G2AF2RL3ALDH1A1
SCHEMBL8172638 0.90 ICMT (0.48) ICMTL3MBTL1POLBPLA2G2AALDH1A1
SCHEMBL8178890 0.90 ICMT (0.47) ICMTL3MBTL1POLBPLA2G2AALDH1A1
SCHEMBL8182894 0.90 HTR6 (0.53) ICMTL3MBTL1POLBPLA2G2AALDH1A1
SCHEMBL13931028 0.88 PPARG (0.56) ICMTL3MBTL1POLBPLA2G2AF2RL3
SCHEMBL8181059 0.87 CHRNB2 (0.58) L3MBTL1POLBPLA2G2AF2RL3ALDH1A1
SCHEMBL8186659 0.87 ICMT (0.49) ICMTL3MBTL1POLBPLA2G2AALDH1A1
SCHEMBL8172186 0.87 POLB (0.53) ICMTL3MBTL1POLBPLA2G2AF2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS ICMT 2415/4885L3MBTL1 2670/4885POLB 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.